Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions

Giuseppe Del Priore, Pamela Smith, David P. Warshal, Brent Dubeshter, Cynthia Angel

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The development of paclitaxel-containing chemotherapeutic regimens has been hindered by the frequent occurrence of allergic-type reactions to the drug or its diluent. Fortunately, current pretreatment regimens are associated with a reduced risk of major hypersensitivity reactions. However, there is still a group of patients that may experience these reactions from Taxol despite the use of prechemotherapy steroids and antihistamines. In a recent report, patients with prior reactions to Taxol were successfully retreated utilizing 24 hr of high-dose steroids and a very prolonged infusion regimen. We now report on two patients with major hypersensitivity reactions despite the use of this regimen. We conclude that not all Taxol-associated hypersensitivity reactions are preventable with current drug regimens. In addition, there is little evidence to support continued or exclusive use of the suggested rechallenge premedication schedule or the prolonged infusion rate.

Original languageEnglish (US)
Pages (from-to)316-318
Number of pages3
JournalGynecologic Oncology
Volume56
Issue number2
DOIs
StatePublished - Feb 1995

Fingerprint

Paclitaxel
Hypersensitivity
Steroids
Premedication
Histamine Antagonists
Pharmaceutical Preparations
Appointments and Schedules

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions. / Del Priore, Giuseppe; Smith, Pamela; Warshal, David P.; Dubeshter, Brent; Angel, Cynthia.

In: Gynecologic Oncology, Vol. 56, No. 2, 02.1995, p. 316-318.

Research output: Contribution to journalArticle

Del Priore, Giuseppe ; Smith, Pamela ; Warshal, David P. ; Dubeshter, Brent ; Angel, Cynthia. / Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions. In: Gynecologic Oncology. 1995 ; Vol. 56, No. 2. pp. 316-318.
@article{a2ccc8fd7b124c58a6e24dfa4796fab9,
title = "Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions",
abstract = "The development of paclitaxel-containing chemotherapeutic regimens has been hindered by the frequent occurrence of allergic-type reactions to the drug or its diluent. Fortunately, current pretreatment regimens are associated with a reduced risk of major hypersensitivity reactions. However, there is still a group of patients that may experience these reactions from Taxol despite the use of prechemotherapy steroids and antihistamines. In a recent report, patients with prior reactions to Taxol were successfully retreated utilizing 24 hr of high-dose steroids and a very prolonged infusion regimen. We now report on two patients with major hypersensitivity reactions despite the use of this regimen. We conclude that not all Taxol-associated hypersensitivity reactions are preventable with current drug regimens. In addition, there is little evidence to support continued or exclusive use of the suggested rechallenge premedication schedule or the prolonged infusion rate.",
author = "{Del Priore}, Giuseppe and Pamela Smith and Warshal, {David P.} and Brent Dubeshter and Cynthia Angel",
year = "1995",
month = "2",
doi = "10.1006/gyno.1995.1054",
language = "English (US)",
volume = "56",
pages = "316--318",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Paclitaxel-associated hypersensitivity reaction despite high-dose steroids and prolonged infusions

AU - Del Priore, Giuseppe

AU - Smith, Pamela

AU - Warshal, David P.

AU - Dubeshter, Brent

AU - Angel, Cynthia

PY - 1995/2

Y1 - 1995/2

N2 - The development of paclitaxel-containing chemotherapeutic regimens has been hindered by the frequent occurrence of allergic-type reactions to the drug or its diluent. Fortunately, current pretreatment regimens are associated with a reduced risk of major hypersensitivity reactions. However, there is still a group of patients that may experience these reactions from Taxol despite the use of prechemotherapy steroids and antihistamines. In a recent report, patients with prior reactions to Taxol were successfully retreated utilizing 24 hr of high-dose steroids and a very prolonged infusion regimen. We now report on two patients with major hypersensitivity reactions despite the use of this regimen. We conclude that not all Taxol-associated hypersensitivity reactions are preventable with current drug regimens. In addition, there is little evidence to support continued or exclusive use of the suggested rechallenge premedication schedule or the prolonged infusion rate.

AB - The development of paclitaxel-containing chemotherapeutic regimens has been hindered by the frequent occurrence of allergic-type reactions to the drug or its diluent. Fortunately, current pretreatment regimens are associated with a reduced risk of major hypersensitivity reactions. However, there is still a group of patients that may experience these reactions from Taxol despite the use of prechemotherapy steroids and antihistamines. In a recent report, patients with prior reactions to Taxol were successfully retreated utilizing 24 hr of high-dose steroids and a very prolonged infusion regimen. We now report on two patients with major hypersensitivity reactions despite the use of this regimen. We conclude that not all Taxol-associated hypersensitivity reactions are preventable with current drug regimens. In addition, there is little evidence to support continued or exclusive use of the suggested rechallenge premedication schedule or the prolonged infusion rate.

UR - http://www.scopus.com/inward/record.url?scp=0028907671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028907671&partnerID=8YFLogxK

U2 - 10.1006/gyno.1995.1054

DO - 10.1006/gyno.1995.1054

M3 - Article

C2 - 7896206

AN - SCOPUS:0028907671

VL - 56

SP - 316

EP - 318

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -